KOD Kodiak Sciences Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1468748 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-13.5%
TTM EPS YoY1.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,360.9%
ROA-115.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets94.0%
Debt / equity0.00x
Current ratio1.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-36.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $182.37M | $126.09M | $206.30M | $267.59M | $217.34M |
| SG&A expense | $52.02M | $60.75M | $71.02M | $73.79M | $49.71M |
| Operating income | -$234.39M | -$186.85M | -$277.32M | -$341.38M | -$267.05M |
| Interest expense | $0 | $0 | $13,000 | $18,000 | $47,000 |
| Pretax income | -$229.91M | -$176.19M | -$260.43M | -$333.79M | -$266.92M |
| Income tax | $52,000 | $20,000 | $33,000 | $33,000 | $74,000 |
| Net income | -$229.97M | -$176.21M | -$260.49M | -$333.82M | -$266.99M |
| EBITDA | -$216.06M | -$168.14M | -$259.02M | -$337.58M | -$266.05M |
| EPS (basic) | -4.32 | -3.35 | -4.97 | -6.39 | -5.16 |
| EPS (diluted) | -4.32 | -3.35 | -4.97 | -6.39 | -5.16 |
| Weighted avg. shares (diluted) | 53.21M | 52.58M | 52.41M | 52.25M | 51.79M |
| Balance sheet | |||||
| Cash & equivalents | $209.86M | $168.07M | $285.51M | $190.43M | $731.51M |
| Short-term investments | — | — | $0 | $288.50M | $0 |
| Current assets | $214.82M | $171.94M | $289.31M | $486.00M | $734.81M |
| PP&E, net | $85.26M | $102.22M | $120.48M | $56.38M | $41.33M |
| Total assets | $351.53M | $335.58M | $479.37M | $666.63M | $904.22M |
| Current liabilities | $45.53M | $25.57M | $41.73M | $52.50M | $64.68M |
| Total liabilities | $194.15M | $185.29M | $213.59M | $230.46M | $240.90M |
| Shareholders' equity | $157.38M | $150.29M | $265.78M | $436.17M | $663.32M |
| Shares outstanding | 61.76M | 52.73M | 52.51M | 52.33M | 51.83M |
| Cash flow statement | |||||
| Operating cash flow | -$136.01M | -$117.32M | -$154.18M | -$206.46M | -$182.27M |
| Capital expenditure | $506,000 | $375,000 | $41.35M | $37.02M | $17.03M |
| Free cash flow | -$136.51M | -$117.69M | -$195.53M | -$243.48M | -$199.30M |
| Investing cash flow | -$506,000 | -$755,000 | $249.23M | -$336.51M | -$38.80M |
| Financing cash flow | $178.30M | $501,000 | $31,000 | $1.90M | $8.18M |
| Depreciation & amortization | $18.33M | $18.71M | $18.30M | $3.80M | $1.00M |
| Stock-based compensation | $58.86M | $60.21M | $88.56M | $106.03M | $61.38M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.